Charles Montano, MD
Internal Medicine · Cromwell, CTNPI 1487673208
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 58 manufacturers reported payments, led by AbbVie at 29.9% of the total. 2025 is the largest year on record at $291,917, 2.5 times the $114,876 reported in 2019. Among internal medicine clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,214 payments — averaging $438.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$290K
- Axsome Therapeutics, Inc.$169K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$130K
- Otsuka America Pharmaceutical, Inc.$64K
- Eisai Inc.$61K
- Takeda Pharmaceuticals U.S.A., Inc.$37K
- plus $219K from 52 others
Across 470 payments — averaging $4206.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$310K
- Boehringer Ingelheim International GmbH$264K
- Supernus Pharmaceuticals, Inc.$260K
- Sage Therapeutics, LLC$252K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$176K
- Pfizer$129K
- plus $586K from 14 others
What the payments were for
- Consulting fees$253,18726%
- Speaking & faculty fees$578,98660%
- Travel & lodging$96,48910%
- Food & beverage$38,9624%
- Education$2,3640%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$969,987 in reported general payments places this provider in the 95th percentile of 2,067 internal medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 73 | $109,726 |
| MounjaroTirzepatide | 88 | $101,655 |
| AuvelityDextromethorphan Hbr/Bupropion | 47 | $59,565 |
| FarxigaDapagliflozin Propanediol | 24 | $37,058 |
| VraylarCariprazine Hcl | 23 | $34,276 |
| RexultiBrexpiprazole | 18 | $33,593 |
| GimotiMetoclopramide Hcl | 12 | $25,311 |
| Repatha SureclickEvolocumab | 27 | $23,958 |
| EliquisApixaban | 23 | $21,417 |
| VascepaIcosapent Ethyl | 36 | $20,927 |
| Nurtec OdtRimegepant Sulfate | 17 | $19,409 |
| VyvanseLisdexamfetamine Dimesylate | 38 | $14,385 |
| TrintellixVortioxetine Hydrobromide | 19 | $13,253 |
| JanumetSitagliptin Phos/Metformin Hcl | 11 | $9,430 |
| Spiriva RespimatTiotropium Bromide | 12 | $6,502 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $3,312 | $109,72673 claims |
| Lilly USA, LLCMounjaro | $2,191 | $101,65588 claims |
| Axsome Therapeutics, Inc.Auvelity | $169,274 | $59,56547 claims |
| AstraZenecaFarxiga, Symbicort | $1,596 | $41,53135 claims |
| PfizerEliquis, Nurtec Odt | $274 | $40,82640 claims |
| AbbVieVraylar, Synthroid, Armour Thyroid | $289,600 | $36,71549 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $64,494 | $33,59318 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix | $36,797 | $27,63857 claims |
| Evoke Pharma, Inc.Gimoti | $10,684 | $25,31112 claims |
| MerckJanumet | $101 | $9,43011 claims |
| Boehringer IngelheimSpiriva Respimat | $6,517 | $6,50212 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $7,051 | $5,36611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,067 internal medicine providers in Connecticut.
Other internal medicine in Cromwell
- Steven RyderWestport$3.9M
- Nancy BrownNew Haven$1.6M
- Arthur DecillisMadison$1M
- Gary BlickNorwalk$683K
- Scott GottliebStamford$508K
- Jeffrey KatzOxford$361K
- Nicholas DainiakBridgeport$352K
- Thomas PellechiGreenwich$196K
- John PriceGlastonbury$188K
- Richard LiftonNew Haven$160K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.